Evidence map›Paper›PMID 32095323›Full record

ArticlePeerJ2020

Downregulation of miR-193a-3p is involved in the pathogenesis of hepatocellular carcinoma by targeting CCND1.

Shi-Shuo Wang, Zhi-Guang Huang, Hua-Yu Wu, Rong-Quan He, Li-Hua Yang, Zhen-Bo Feng, Yi-Wu Dang, Hui-Ping Lu, Ye-Ying Fang, Gang Chen

Open access · goldAbstract read
In one paragraph

Article in PeerJ, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Frontiers in genetics · 2023
    Article
  5. Article
  6. Article
  7. Mig-6 Inhibits Autophagy in HCC Cell Lines by Modulating miR-193a-3p.International journal of medical sciences · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Shi-Shuo Wang *Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Zhi-Guang Huang *Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Hua-Yu WuDepartment of Cell Biology & Genetics, Guangxi Medical University, Nanning, Guangxi, China.
Rong-Quan HeDepartment of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Li-Hua YangDepartment of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Zhen-Bo FengDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Yi-Wu DangDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Hui-Ping LuDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Ye-Ying FangDepartment of Radiation Oncology, Radiation Oncology Clinical Medical Research Center of Guangxi, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Gang ChenDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Guangxi Medical University · CNFirst Affiliated Hospital of GuangXi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is the second-highest cause of malignancy-related death worldwide, and many physiological and pathological processes, including cancer, are regulated by microRNAs (miRNAs). miR-193a-3p is an anti-oncogene that plays an important part in health and disease biology by interacting with specific targets and signals.

methodsIn vitro assays were performed to explore the influences of miR-193a-3p on the propagation and apoptosis of HCC cells. The sequencing data for HCC were obtained from The Cancer Genome Atlas (TCGA), and the expression levels of miR-193a-3p in HCC and non-HCC tissues were calculated. The differential expression of miR-193a-3p in HCC was presented as standardized mean difference (SMD) with 95% confidence intervals (CIs) in Stata SE. The impact of miR-193a-3p on the prognoses of HCC patients was determined by survival analysis. The potential targets of miR-193a-3p were then predicted using miRWalk 2.0 and subjected to enrichment analyses, including Gene Ontology (GO) annotation, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and Protein-Protein Interaction (PPI) network analysis. The interaction between miR-193a-3p and one predicted target, Cyclin D1 (CCND1), was verified by dual luciferase reporter assays and Pearson correlation analysis.

resultsMiR-193a-3p inhibited the propagation and facilitated the apoptosis of HCC cells

conclusionmiR-193a-3p could suppress proliferation and promote apoptosis by targeting CCND1 in HCC cells. Further, miR-193a-3p can be used as a promising biomarker for the diagnosis and treatment of HCC in the future.

Indexed as

ApoptosisBioinformaticsCell proliferationCyclin D1Hepatocellular CarcinomaMir-193a-3p

Identifiers

PMID32095323
PMCPMC7017797
OpenAlexW3004623056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.